• Decrease
  • Normal
  • Increase
U.S. Department of Health and Human Services

About FDA

Percentage of approval letters reviewed for disclosure and posted on the web within 5 business days of receipt in OCOD, excluding days that the Web Content Management System (WCMS) is not operational. (1)

Dictionary: An approval letter is the document used to communicate CBER’s approval of original and supplemental biologics license applications (BLAs) or new drug application (NDAs). OCOD is responsible for ensuring CBER approval letters are reviewed for disclosure and posted on the agency's web site to conform to all pertinent requirements. Expedient posting of approval letters will provide up to date information to the public.

Information is current as of June 30, 2014

Fiscal Year - 2014

Skip graphic and jump to text data

TimeTargetPercent
October – December 20139096
January – March 201490100
April – June 201490100
July – September 201490TBD

FY 2014 YTD: 98%

Footnotes

  • (1) Beginning October 2012, this measure will be reported quarterly

Number of approval letters provided to OCOD for posting this quarter.

Fiscal Year - 2014
Skip graphic and jump to text data.

TimeTargetNumber
October – December 2013N/A28
January – March 2014N/A16
April – June 2014N/A19
July – September 2014N/ATBD

FY 2014 YTD: 63

Number of approval letters that were posted on time (within 5 business days, excluding days WCMS is not operational) during the quarter.

Fiscal Year - 2014
Skip graphic and jump to text data.

TimeTargetNumber
October – December 2013N/A27
January – March 2014N/A16
April – June 2014N/A19
July – September 2014N/ATBD

FY 2014 YTD: 62

Number of approval letters that were not posted within 5 business days, excluding days that WCMS is not operational.

Fiscal Year - 2014
Skip graphic and jump to text data.

TimeTargetNumber
October – December 2013N/A1
January – March 2014N/A0
April – June 2014N/A0
July – September 2014N/ATBD

FY 2014 YTD: 1

Glossary

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.